Subscribe

DIVA Laboratories, Ltd. (4153.TWO)

TWD31.40 +0.15 (+0.48%)
TW TWO Healthcare Medical - Diagnostics & Research
Address No. 351, Zhongshan Rd. 235
New Taipei City, TW
CEO Chen Gene
Website diva.com.tw
IPO 2012-07-17
ISIN TW0004153002

Explore sections of this company profile

Description

DIVA Laboratories, Ltd. specializes in the global provision of advanced display technologies. Its comprehensive product lineup caters to critical environments, including specialized endo/surgical displays designed to render both static and dynamic imagery with precision for hybrid and integrated operating theaters, as well as crucial control room applications. Furthermore, DIVA offers a range of color and monochrome monitors tailored for high-accuracy radiology and broader medical imaging purposes. Beyond healthcare, the company develops interactive touch displays and human-machine interface (HMI) solutions, alongside robust medical and industrial enclosures. DIVA also serves original design manufacturers (ODMs) and original equipment manufacturers (OEMs) with custom display units, in addition to a broader portfolio of video solutions. Established in 1995, DIVA Laboratories, Ltd. maintains its corporate headquarters in New Taipei City, Taiwan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD31.40 +0.15 (+0.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
38.0K
Beta
0.20
Float Shares
54.08M
Free Float %
92.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.16% -4.52% -6.13% -7.27% -17.63% -12.32% -27.40% -36.84% +33.33% -54.87% +127.34%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
31.40
DCF (Unlevered) 63.74 +103.0%
DCF (Levered) 41.82 +33.2%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.96
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +0.8% Q1'26: +7.6% (vs Q1'25)
  • ✗
    EPS growth Medical - Diagnostics & Research: +30.8%
    -3.1% Q1'26: +0.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +2.5% Q1'26: +2.4% (vs Q1'25)
  • ✗
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +11.8% ★ Q1'26: +12.2% (vs Q1'25)
  • ✓
    ROIC Medical - Diagnostics & Research: +5.2%
    +15.8% ★ Q1'26: +18.5% (vs Q1'25)
  • ✓
    Share dilution Medical - Diagnostics & Research: 0.0%
    -0.2% ★ Q1'26: -0.4% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    0.03× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.30) × ERP
WACC = 100% × Ke + 0% × Kd (4.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 63.74 Current price: 31.40
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
1.34B
est.
1.00B
est.
1.18B
est.
716.17M
est: 740.00M (-3.2%)
736.93M
est: 900.00M (-18.1%)
862.32M
est: 1.00B (-14.1%)
868.84M
est: 1.00B (-13.5%)
1.18B
1.18B – 1.18B
+17.2% YoY
740.00M
740.00M – 740.00M
-37.1% YoY
740.00M
740.00M – 740.00M
+0.0% YoY
900.00M
900.00M – 900.00M
+21.6% YoY
EBITDA
151.44M
est.
113.23M
est.
132.72M
est.
84.06M
est: 83.45M (+0.7%)
77.72M
est: 101.49M (-23.4%)
127.10M
est: 176.99M (-28.2%)
102.26M
est: 176.99M (-42.2%)
207.46M
207.46M – 207.46M
+17.2% YoY
130.43M
130.43M – 130.43M
-37.1% YoY
130.43M
130.43M – 130.43M
+0.0% YoY
158.64M
158.64M – 158.64M
+21.6% YoY
EBIT
130.61M
est.
97.66M
est.
114.47M
est.
65.45M
est: 71.97M (-9.1%)
27.61M
est: 87.53M (-68.5%)
116.16M
est: 192.57M (-39.7%)
102.26M
est: 192.57M (-46.9%)
225.72M
225.72M – 225.72M
+17.2% YoY
141.92M
141.92M – 141.92M
-37.1% YoY
141.92M
141.92M – 141.92M
+0.0% YoY
172.60M
172.60M – 172.60M
+21.6% YoY
Net Income
252.61M
est.
27.19M
est.
119.38M
est.
56.04M
est: 66.32M (-15.5%)
17.42M
est: 94.18M (-81.5%)
93.66M
est: 27.13M (+245.2%)
90.54M
est: 27.13M (+233.7%)
119.12M
119.12M – 119.12M
+339.0% YoY
66.18M
66.18M – 66.18M
-44.4% YoY
66.18M
66.18M – 66.18M
+0.0% YoY
93.97M
93.97M – 93.97M
+42.0% YoY
SGA
143.43M
est.
107.24M
est.
125.70M
est.
94.20M
est: 79.03M (+19.2%)
83.10M
est: 96.12M (-13.5%)
85.71M
est: 84.60M (+1.3%)
—
est: 84.60M (-100.0%)
99.16M
99.16M – 99.16M
+17.2% YoY
62.34M
62.34M – 62.34M
-37.1% YoY
62.34M
62.34M – 62.34M
+0.0% YoY
75.82M
75.82M – 75.82M
+21.6% YoY
EPS
4.29
est.
0.46
est.
2.03
est.
0.78
est: 1.13 (-30.7%)
0.26
est: 1.60 (-83.7%)
1.60
est: 0.46 (+246.7%)
1.54
est: 0.46 (+233.7%)
2.03
2.03 – 2.03
+339.0% YoY
1.13
1.13 – 1.13
-44.4% YoY
1.13
1.13 – 1.13
+0.0% YoY
1.60
1.60 – 1.60
+42.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-04-30 A- 4/5 4/5 3/5 5/5 3/5 3/5 3/5
2026-04-29 A- 4/5 4/5 3/5 5/5 3/5 3/5 3/5
2026-04-28 A- 4/5 4/5 3/5 5/5 3/5 3/5 3/5
2026-04-27 A- 4/5 4/5 3/5 5/5 3/5 3/5 3/5
2026-04-24 A- 4/5 4/5 3/5 5/5 3/5 3/5 3/5
2026-04-23 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-22 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-21 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-20 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-17 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-16 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
60.51M
OE per share TTM
1.03
Owner's Yield
3.35%
Maintenance CapEx ratio
4.11%
Maint CapEx / Avg PPE
27.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
664.0K
Shares Outstanding
58.67M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chen Gene Vice Chairman & CEO — —
James Chen Vice President & Chief Technology Officer — —
Jian Gen Zhang Deputy General Manager of the Development Department — —
Jun Xian Li Director of the Information Department — —
Kenneth Chen Chief SO — —
Peter Chang Chief Operating Officer — —
Su Ru Lin Accounting Supervisor — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research